2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation
Documentos PDF
Summary in foreign language
Introduction
Several recent case reports have described common early chest imaging findings of lung pathology caused by 2019 novel Coronavirus (SARS-COV2) which appear to be similar to those seen previously in SARS-CoV and MERS-CoV infected patients.
Objective
We present some remarkable imaging findings of the first two patients identified in Italy with COVID-19 infection travelling from Wuhan, China. The follow-up with chest X-Rays and CT scans was also included, showing a progressive adult respiratory distress syndrome (ARDS).
Results
Moderate to severe progression of the lung infiltrates, with increasing percentage of high-density infiltrates sustained by a bilateral and multi-segmental extension of lung opacities, were seen. During the follow-up, apart from pleural effusions, a tubular and enlarged appearance of pulmonary vessels with a sudden caliber reduction was seen, mainly found in the dichotomic tracts, where the center of a new insurgent pulmonary lesion was seen. It could be an early alert radiological sign to predict initial lung deterioration. Another uncommon element was the presence of mediastinal lymphadenopathy with short-axis oval nodes.
Conclusions
Although only two patients have been studied, these findings are consistent with the radiological pattern described in literature. Finally, the pulmonary vessels enlargement in areas where new lung infiltrates develop in the follow-up CT scan, could describe an early predictor radiological sign of lung impairment.
Link to resource
https://www.sciencedirect.com/science/article/pii/S1201971220301016Collections
Estadísticas Google Analytics
Comments
Related items
Showing items related by title, author, creator and subject.
-
Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19)
(Cell Death & Differentiation, 2020-06-08) -
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses
(Drug Resistance Updates, 2020)
